IP Library Granted Patent US 11,097,014
Granted Patent B2
US 11,097,014 · App. 16/310,104 · Granted Aug 24, 2021

Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles

Inventors: Jianjun Chen (Cincinnati, OH); Seungpyo Hong (Naperville, IL); Xi Jiang (Cincinnati, OH); Zejuan Li (Chicago, IL)
Assignees: University of Cincinnati; Board of Trustees of the University of Illinois; University of Chicago
A61K47/6935A61K31/551A61K31/7105A61K38/19A61K45/06A61K47/595A61K47/62A61P35/02C12N15/1138C12N2310/141C12N2310/321
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,097,014
App. No.
16/310,104
Granted
Aug 24, 2021
Kind
B2
Abstract

A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Claims (8)

1. A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor;

wherein the ligand specific for FLT3 receptor consists of a synthetic FLT3L peptide having at least 90% sequence homology to SEQ ID NO: 1.

2. The delivery system according to claim 1 , wherein the PAMAM dendrimers comprise between generation-2 and generation-8 dendrimers.

3. The delivery system according to claim 1 , wherein the PAMAM dendrimers comprise generation 7 (G7) dendrimers.

4. The delivery system according to claim 1 wherein the synthetic FLT3L peptide is Flt3L peptide consisting of SEQ ID NO: 1.

5. The delivery system according to claim 1 , wherein the miR-150 is modified for stability.

6. The delivery system according to claim 5 , wherein the miR-150 stability modification comprises 2′-O methylation.

7. The nanoparticle delivery system according to claim 1 comprising G7-Flt3L-(2′OMe)miR-150.

Assignments (4)
CONFIRMATORY LICENSE Recorded Feb 15, 2023
From: UNIVERSITY OF CINCINNATI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062760/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2019
From: CHEN, JIANJUN; JIANG, XI
To: UNIVERSITY OF CINCINNATI
Reel/Frame 048506/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2019
From: HONG, SEUNGPYO
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 048506/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2019
From: LI, ZEJUAN
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 048506/0425 →
Continuity (2)
Provisional Application 62349707 · Jun 14, 2016
Related Publication 20190175754A1 · Jun 13, 2019